The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...

数十年来肺癌罹患机率整体下降，但不曾抽烟的亚裔美国人得肺癌机率却越来越高; 示意图。（图/123RF） 雅虎生活新闻（Yahoo Life）27日报导，专门研究亚裔美国人未抽烟却得肺癌趋势的斯坦福大学（Stanford ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

Regenerative medicine has the potential to reshape how we treat diseases, offering new hope for patients requiring cell, ...

Dr. Bryant Lin, a Stanford University School of Medicine physician and professor, has never smoked, but in early May 2024, he ...

Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...

Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data ...

Metropolis molecular genomics study shows genetic profiling are improving survival rates: Our Bureau, Bengaluru Friday, November 22, 2024, 14:45 Hrs [IST] Metropolis Healthcare co ...